Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
| ▸ | NMT1 | P30419 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9673792 | 0.80 | SMN1; SMN2 (0.76) | SMN1; SMN2CYP1A2CYP2C19CYP2C9LMNA | |
| SCHEMBL24885393 | 0.80 | SMN1; SMN2 (0.37) | SMN1; SMN2CYP1A2CYP2C19CYP2C9ALDH1A1 | |
| SCHEMBL28757929 | 0.79 | SMN1; SMN2 (0.51) | SMN1; SMN2CYP1A2CYP2C19CYP2C9LMNA | |
| SCHEMBL25109504 | 0.78 | SMN1; SMN2 (0.36) | SMN1; SMN2CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL11478780 | 0.76 | MPO (0.40) | SMN1; SMN2CYP1A2CYP2C19CYP2C9LMNA | |
| SCHEMBL11491239 | 0.76 | SMN1; SMN2 (0.35) | SMN1; SMN2CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL14507097 | 0.74 | CYP2C19 (0.38) | SMN1; SMN2CYP1A2CYP2C19CYP2C9LMNA | |
| SCHEMBL9262737 | 0.74 | SMN1; SMN2 (0.47) | SMN1; SMN2CYP1A2CYP2C19CYP2C9LMNA | |
| SCHEMBL9672301 | 0.74 | SMN1; SMN2 (0.74) | SMN1; SMN2CYP1A2CYP2C19CYP2C9LMNA | |
| SCHEMBL3154381 | 0.74 | SMN1; SMN2 (0.47) | SMN1; SMN2CYP1A2CYP2C19CYP2C9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4655284-A1 | MICROBIOCIDAL PYRAZOLE DERIVATIVES | Syngenta Crop Protection AG (CH) | 2025-12-03 | — | — | EP | disclosed |
| WO-2024156886-A1 | MICROBIOCIDAL PYRAZOLE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2024-08-02 | — | — | WO | disclosed |
| US-10702507-B2 | Endoparasite control agent | THE UNIVERSITY OF TOKYO (JP) | 2020-07-07 | — | — | US | disclosed |
| US-20190046511-A1 | ENDOPARASITE CONTROL AGENT | THE UNIVERSITY OF TOKYO (JP) | 2019-02-14 | — | — | US | disclosed |
| US-20160367532-A1 | ENDOPARASITE CONTROL AGENT | THE UNIVERSITY OF TOKYO (JP) | 2016-12-22 | — | — | US | disclosed |
| US-8735429-B2 | Benzamide compounds useful as histone deacetylase inhibitors | ASTRAZENECA AB (SE) | 2014-05-27 | — | — | US | disclosed |
| EP-1954690-B1 | BENZAMIDE COMPOUNDS USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2013-05-15 | — | — | EP | disclosed |
| US-20120225907-A1 | BENZAMIDE COMPOUNDS USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2012-09-06 | — | — | US | disclosed |
| US-8207202-B2 | N-(2-aminophenyl)-4-{1-[(5-methoxy-1,3-dimethyl-1H-pyrazol-4-yl)methyl]piperidin-4-yl}benzamide, for example; use as an antiproliferative agent in the prevention or treatment of tumors or other proliferative conditions, which are sensitive to the inhibition of histone deacetylase | ASTRAZENECA AB (SE) | 2012-06-26 | — | — | US | disclosed |
| US-20080269294-A1 | N-(2-aminophenyl)-4-{1-[(5-methoxy-1,3-dimethyl-1H-pyrazol-4-yl)methyl]piperidin-4-yl}benzamide, for example; use as an antiproliferative agent in the prevention or treatment of tumors or other proliferative conditions, which are sensitive to the inhibition of histone deacetylase | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| EP-1954690-A1 | BENZAMIDE COMPOUNDS USEFUL AS HISTONE DEACETYLASE INHIBITORS | Astra Zeneca AB (SE) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007045844-A1 | BENZAMIDE COMPOUNDS USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | WO | disclosed |
| US-4226877-A | ANTIPSYCHOTIC AGENTS, SCHIZOPHRENIA | ABBOTT LABORATORIES (US) | 1980-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367532-A1 | ENDOPARASITE CONTROL AGENT | NAAA, CTRL, ENPP1 | SMN1; SMN2 4395/4885CYP1A2 1264/4885CYP2C19 742/4885 |
| US-20120225907-A1 | BENZAMIDE COMPOUNDS USEFUL AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC5 | SMN1; SMN2 3208/4885CYP1A2 1090/4885CYP2C19 795/4885 |
| US-20080269294-A1 | N-(2-aminophenyl)-4-{1-[(5-methoxy-1,3-dimethyl-1H-pyrazol-4-yl)methyl]piperidin-4-yl}benzamide, for example; use as an antiproliferative agent in the prevention or treatment of tumors or other proliferative conditions, which are sensitive to the inhibition of histone deacetylase | HDAC1, HDAC5, HDAC2 | SMN1; SMN2 1810/4885CYP1A2 1901/4885CYP2C19 2023/4885 |
| US-20190046511-A1 | ENDOPARASITE CONTROL AGENT | NAAA, CTRL, ENPP1 | SMN1; SMN2 4395/4885CYP1A2 1264/4885CYP2C19 742/4885 |
| US-10702507-B2 | Endoparasite control agent | NAAA, CTRL, ENPP1 | SMN1; SMN2 4395/4885CYP1A2 1264/4885CYP2C19 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.